The efficacy and safety of sorafenib in older adults with advanced hepatocellular carcinoma: An analysis of a majority Hispanic cohort.
作者信息
Arora Sukeshi Patel, Ananth Snegha, Ketchum Norma, Gelfond Jonathan, Michalek Joel, Mahalingam Devalingam
机构信息
Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, USA.
Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, USA.
出版信息
J Geriatr Oncol. 2020 Sep;11(7):1157-1160. doi: 10.1016/j.jgo.2020.03.018. Epub 2020 Apr 6.
Abstract
摘要
相似文献
1
The efficacy and safety of sorafenib in older adults with advanced hepatocellular carcinoma: An analysis of a majority Hispanic cohort.索拉非尼在老年晚期肝细胞癌患者中的疗效和安全性：一项针对多数为西班牙裔队列的分析。
J Geriatr Oncol. 2020 Sep;11(7):1157-1160. doi: 10.1016/j.jgo.2020.03.018. Epub 2020 Apr 6.
2
Sorafenib-induced liver failure in a hepatocellular carcinoma patient: Letter to the editor.索拉非尼诱发肝细胞癌患者肝衰竭：致编辑的信
Clin Res Hepatol Gastroenterol. 2022 Jun-Jul;46(6):101931. doi: 10.1016/j.clinre.2022.101931. Epub 2022 Apr 25.
3
Tolerability of single-agent sorafenib in the treatment of elderly patients with hepatocellular carcinoma (HCC).索拉非尼单药治疗老年肝细胞癌（HCC）患者的耐受性
Hepatology. 2014 Aug;60(2):764-5. doi: 10.1002/hep.26921.
4
[Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].索拉非尼治疗晚期肝细胞癌的现状与未来展望
Nihon Shokakibyo Gakkai Zasshi. 2012 Aug;109(8):1346-54.
5
Abdominal aortic dissection during sorafenib therapy for hepatocellular carcinoma.索拉非尼治疗肝细胞癌期间发生腹主动脉夹层。
Clin Res Hepatol Gastroenterol. 2017 Mar;41(2):e24-e25. doi: 10.1016/j.clinre.2016.12.005. Epub 2017 Feb 3.
6
A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.一例晚期肝细胞癌中与索拉非尼相关的可逆性心肌病病例。
Int J Cardiol. 2012 Sep 20;160(1):e10-1. doi: 10.1016/j.ijcard.2011.12.114. Epub 2012 Jan 29.
7
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.钇[90Y]树脂微球选择性内放射治疗与索拉非尼治疗局部进展期不可切除肝细胞癌的疗效和安全性比较（SARAH）：一项开放标签随机对照 3 期临床试验。
Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26.
8
Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?从索拉非尼治疗晚期肝细胞癌7年经验中学习：索拉非尼是否优于索拉非尼？
Target Oncol. 2016 Aug;11(4):565-7. doi: 10.1007/s11523-016-0427-8.
9
Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma.索拉非尼治疗老年晚期肝细胞癌患者的疗效和安全性。
Clinics (Sao Paulo). 2021 Jan 22;76:e2498. doi: 10.6061/clinics/2021/e2498. eCollection 2021.
10
Exacerbation of psoriasis vulgaris by sorafenib treatment for hepatocellular carcinoma.索拉非尼治疗肝细胞癌导致寻常型银屑病恶化。
Clin J Gastroenterol. 2020 Oct;13(5):891-895. doi: 10.1007/s12328-020-01134-3. Epub 2020 May 28.
引用本文的文献
1
A scoping review of racial, ethnic, socioeconomic, and geographic disparities in the outcomes of older adults with cancer.一项针对老年癌症患者结局的种族、民族、社会经济和地理差异的范围综述。
J Am Geriatr Soc. 2024 Jun;72(6):1867-1900. doi: 10.1111/jgs.18881. Epub 2024 Apr 9.
2
Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma.索拉非尼治疗老年肝细胞癌患者的生存情况及不良事件
Front Oncol. 2022 Aug 2;12:829483. doi: 10.3389/fonc.2022.829483. eCollection 2022.
本文引用的文献
1
Hepatocellular carcinoma in older adults: A comprehensive review by Young International Society of Geriatric Oncology.老年肝细胞癌：国际老年肿瘤学会青年委员会的全面综述
J Geriatr Oncol. 2020 May;11(4):557-565. doi: 10.1016/j.jgo.2019.10.007. Epub 2019 Nov 6.
2
High cancer mortality for US-born Latinos: evidence from California and Texas.美国出生的拉丁裔癌症死亡率高：来自加利福尼亚州和得克萨斯州的证据。
BMC Cancer. 2017 Jul 11;17(1):478. doi: 10.1186/s12885-017-3469-0.
3
Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients With Cancer.癌症种族和少数民族患者临床试验入组的障碍
Cancer Control. 2016 Oct;23(4):327-337. doi: 10.1177/107327481602300404.
4
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem.索拉非尼治疗晚期肝细胞癌患者的疗效与安全性：年龄并非问题。
Eur J Gastroenterol Hepatol. 2017 Jan;29(1):48-55. doi: 10.1097/MEG.0000000000000739.
5
Hepatocellular carcinoma in elderly patients: challenges and solutions.老年肝细胞癌：挑战与解决方案。
J Hepatocell Carcinoma. 2016 Jun 17;3:9-18. doi: 10.2147/JHC.S101448. eCollection 2016.
6
A novel and accurate predictor of survival for patients with hepatocellular carcinoma after surgical resection: the neutrophil to lymphocyte ratio (NLR) combined with the aspartate aminotransferase/platelet count ratio index (APRI).一种用于预测肝细胞癌患者手术切除后生存情况的新型且准确的指标：中性粒细胞与淋巴细胞比值（NLR）联合天冬氨酸氨基转移酶/血小板计数比值指数（APRI）。
BMC Cancer. 2016 Feb 22;16:137. doi: 10.1186/s12885-016-2189-1.
7
Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction.索拉非尼在不同肝功能损害的肝细胞癌患者中的剂量比较及疗效观察
J Gastrointest Oncol. 2015 Jun;6(3):259-67. doi: 10.3978/j.issn.2078-6891.2015.005.
8
Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors.索拉非尼在老年肝细胞癌患者中的应用：使用血小板聚集抑制剂时需谨慎。
Cancer Chemother Pharmacol. 2015 Jan;75(1):215-9. doi: 10.1007/s00280-014-2645-z. Epub 2014 Dec 5.
9
Incidence of hepatocellular carcinoma in Texas Latinos, 1995-2010: an update.1995 - 2010年得克萨斯州拉丁裔肝细胞癌发病率：最新情况
PLoS One. 2014 Jun 10;9(6):e99365. doi: 10.1371/journal.pone.0099365. eCollection 2014.
10
Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma.索拉非尼在80岁及以上老年晚期肝细胞癌患者中的疗效和安全性。
Hepatol Res. 2014 Dec;44(13):1329-38. doi: 10.1111/hepr.12308. Epub 2014 Apr 2.
Zotero 插件